RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA(AML)

Clinical trials for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA(AML) explained in plain language.

Never miss a new study

Get alerted when new RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA(AML) trials appear

Sign up with your email to follow new studies for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA(AML), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet recruiting 2 Not yet finished but already full! 1

Experimental drug aims to rally immune system against tough blood cancers

Disease control Recruiting now

This is the first study in people of an experimental drug called CLN-049 for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has returned or stopped responding to standard treatments. The main goals are to find a safe dose and see how the drug move…

Matched conditions: RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA(AML)

Phase: PHASE1 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control

Last updated Mar 30, 2026 14:31 UTC

RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA(AML)

Get alerted when new RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA(AML) trials appear

Experimental drug aims to rally immune system against tough blood cancers